Imatinib

🧮 Dose calculator

Chronic myeloid leukaemia (CML) and GIST · Regimen source: FDA Imatinib · 2.2

• • Only under an oncologist; dose is adjusted by response and toxicity. FDA Imatinib · 2
• • With a meal and a large glass of water. 400 and 600 mg once daily; 800 mg as 400 mg twice daily. With strong CYP3A4 inducers increase by at least 50%. FDA Imatinib · 2.1FDA Imatinib · 2.12

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Imatinib · 8.1

  “Risk Summary Imatinib mesylate can cause fetal harm when administered to a pregnant woman based on human and animal data.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Imatinib · 8.2

  “Because of the potential for serious adverse reactions in breastfed infants from imatinib mesylate, advise a lactating woman not to breastfeed during treatment and for 1 month after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Imatinib · 8.4

  “The safety and effectiveness of imatinib mesylate have been demonstrated in pediatric patients with newly diagnosed Ph+ chronic phase CML and Ph+ ALL [see Clinical Studies ( 14.2 , 14.4 ) ] .”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Imatinib · 8.5

  “The frequency of edema was higher in patients older than 65 years as compared to younger patients; no other difference in the safety profile was observed [see Warnings and Precautions ( 5.1 )] .”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Imatinib · 8.3

  “Contraception Females Advise female patients of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) when using imatinib mesylate during treatment and for fourteen days after stopping treatment with imatinib mesylate [see Specific Populations ( 8 )] .”